THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer or registered institution in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Huisheng International Holdings Limited (the "Company"), you should at once hand this circular and the accompanying form of proxy to the purchaser or the transferee or to the bank, licensed securities dealer or registered institution in securities or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



HUISHENG INTERNATIONAL HOLDINGS LIMITED

惠生國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1340)

- (1) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES;
 - (2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND APPOINTMENT OF DIRECTOR:
 - (3) REFRESHMENT OF SCHEME MANDATE LIMIT AND
 - (4) NOTICE OF ANNUAL GENERAL MEETING

A notice convening an annual general meeting of the Company to be held at Room 2302, 23/F., China Insurance Group Building, 141 Des Voeux Road Central, Central, Hong Kong on Thursday, 30 September 2021 at 4:30 p.m. is set out on pages 21 to 26 of this circular. A form of proxy for use at the annual general meeting of the Company is enclosed with this circular. Such form of proxy is also published on the websites of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk and of the Company at www.hsihl.com.

Whether or not you are able to attend the annual general meeting, you are requested to complete the accompanying form of proxy in accordance with the instructions printed thereon and deposit the same at the Company's Hong Kong branch share registrar, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong as soon as possible and in any event not less than 48 hours before (i.e. no later than 4:30 p.m. (Hong Kong Time) on Tuesday, 28 September 2021) the time appointed for the holding of the annual general meeting or its adjournment. Completion and return of the form of proxy will not preclude you from attending and voting in person at the annual general meeting or any adjournment thereof should you so wish.

CONTENTS

	Page
Precautionary Measures for the Annual General Meeting	1
Definitions	2
Letter from the Board	
Introduction	5
General Mandate and Repurchase Mandate	6
Re-election of Retiring Directors and Appointment of Director	7
Refreshment of Scheme Mandate Limit	9
AGM	11
Responsibility Statement	11
Recommendation	12
General	12
Appendix I - Explanatory Statement	13
Appendix II - Details of Directors Proposed to be Re-elected and Appointed at the AGM	16
Notice of ACM	21

PRECAUTIONARY MEASURES FOR THE ANNUAL GENERAL MEETING

The health of our shareholders, staff and stakeholders is of paramount importance to us. In

view of the ongoing Novel Coronavirus (COVID-19) pandemic, the Company will implement the following precautionary measures at the Annual General Meeting to protect attending shareholders,

staff and stakeholders from the risk of infection: –

(i) Compulsory body temperature checks will be conducted for every shareholder, proxy

or other attendee at each entrance of the meeting venue. Any person with a body temperature of over 37.4 degrees Celsius may be denied entry into the meeting venue

or be required to leave the meeting venue.

(ii) The Company encourages each attendee to wear a surgical face mask throughout the

meeting and inside the meeting venue, and to maintain a safe distance between seats.

(iii) No refreshment will be served, and there will be no corporate gift.

In addition, the Company reminds all shareholders that physical attendance in person at the

meeting is not necessary for the purpose of exercising voting rights. Shareholders may appoint the chairman of the meeting as their proxy to vote on the relevant resolution(s) at the meeting instead

of attending the meeting in person, by completing and return the proxy form attached to this

document.

If any shareholder chooses not to attend the meeting in person but has any question about any

resolution or about the Company, or has any matter for communication with the board of directors

of the Company, he/she is welcome to send such question or matter in writing to our registered office or send a message at the Company's website (www.hsihl.com). If any shareholder has any

office of send a message at the company's website (www.nsim.com). If any shareholder has any

question relating to the meeting, please contact Tricor Investor Services Limited, the Company's

branch share registrar in Hong Kong as follows: -

Tricor Investor Services Limited

Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong

Email: is-enquiries@hk.tricorglobal.com

Tel: (852) 2980 1333

Fax: (852) 2810 8185

- 1 -

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions have the following meanings:

"AGM" the annual general meeting of the Company to be convened

and held on Thursday, 30 September 2021 at 4:30 p.m. to consider and, if thought fit, to approve, among other things, the proposed grant of the General Mandate and the Repurchase Mandate, the proposed re-election of retiring Directors and appointment of Director, and the proposed

Refreshment of Scheme Mandate Limit

"Articles" the articles of association of the Company, as amended

from time to time

"Board" the board of Directors

"close associate(s)" has the meaning ascribed to this term under the Listing

Rules

"Company" Huisheng International Holdings Limited, a company

incorporated in the Cayman Islands with limited liability and the issued Shares of which are listed on the main board

of the Stock Exchange

"Director(s)" the director(s) of the Company

"General Mandate" the general mandate proposed to be granted to the Directors

at the AGM to issue further new Shares not exceeding 20% of the number of the issued Shares as at the date of granting

of the General Mandate

"Group" the Company and all of its subsidiaries

"Hong Kong" the Hong Kong Special Administrative Region of the PRC

"Latest Practicable Date" 25 August 2021, being the latest practicable date prior to

the printing of this circular for the purpose of ascertaining

certain information contained in this circular

DEFINITIONS

"Listing Rules" the Rules Governing the Listing of Securities on the Stock

Exchange

"PRC" the People's Republic of China (for the purpose of

this circular, excluding Hong Kong, the Macau Special

Administrative Region and Taiwan)

"Refreshment of Scheme

Mandate Limit"

the proposed refreshment of the Scheme Mandate Limit

under the Share Option Scheme

"Repurchase Mandate" the repurchase mandate proposed to be granted to the

Directors at the AGM to repurchase up to 10% of the number of issued Shares as at the date of granting of the

Repurchase Mandate

"Scheme Mandate Limit" the maximum number of Shares which may be allotted and

issued upon the exercise of all Share Options to be granted under the Share Option Scheme and which shall not in aggregate exceed 10% of the Shares in issue as at the date of the approval of the Share Option Scheme and thereafter, if refreshed shall not exceed 10% of the Shares in issue as at the date of approval of the refreshed limit by the

Shareholders

"SFO" the Securities and Futures Ordinance (Chapter 571 of the

Laws of Hong Kong)

"Share(s)" ordinary share(s) of HK\$0.01 each in the share capital of

the Company

"Share Option(s)" share option(s) to subscribe for Share(s) granted and to be

granted under the Share Option Scheme

"Share Option Scheme" the share option scheme adopted by the Company on 11

February 2014

DEFINITIONS

"Shareholder(s)" holder(s) of the Share(s)

"Stock Exchange" The Stock Exchange of Hong Kong Limited

"Takeovers Code" the Code on Takeovers and Mergers and Share Buy-backs

as approved by the Securities and Futures Commission

"HK\$" Hong Kong dollars, the lawful currency of Hong Kong

"%" per cent.



HUISHENG INTERNATIONAL HOLDINGS LIMITED 惠生國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1340)

Executive Directors:

Mr. Chan Chi Ching

Mr. Suen Man Fung

Mr. Su Hongbo

Independent non-executive Directors:

Mr. Chan Hin Hang

Mr. Wong Yuk Lun, Alan Mr. Wong King Shiu, Daniel

Dr. Wang Guiping

Head office in the PRC:

Unit 4

Hejiaping Housing Committee

Deshan Town

Economic and Technological Development Zone

Changde City, Hunan Province

PRC

Principal place of business in Hong Kong:

Room 1604, 16/F Tower 1, Silvercord 30 Canton Road Tsim Sha Tsui

Kowloon, Hong Kong

Registered office: Cricket Square Hutchins Drive

P.O. Box 2681

Grand Cayman KY1-1111

Cayman Islands

31 August 2021

To the Shareholders

Dear Sir or Madam,

- (1) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES;
- (2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND APPOINTMENT OF DIRECTOR;
 - (3) REFRESHMENT OF SCHEME MANDATE LIMIT AND
 - (4) NOTICE OF ANNUAL GENERAL MEETING

INTRODUCTION

At the forthcoming AGM, resolutions will be proposed to seek the Shareholders' approval for, among other things, (i) the granting of the General Mandate (including the extended General Mandate) and the Repurchase Mandate to the Directors; (ii) the re-election of Directors and appointment of Director; and (iii) the Refreshment of Scheme Mandate Limit.

The purpose of this circular is to provide you with information relating to the resolutions to be proposed at the AGM for the proposed grant of the General Mandate (including the extended General Mandate) and the Repurchase Mandate, the proposed re-election of Directors and appointment of Director, the proposed Refreshment of Scheme Mandate limit and the notice of the AGM.

GENERAL MANDATE AND REPURCHASE MANDATE

At the AGM, the Directors propose to seek the approval of the Shareholders to grant to the Directors the General Mandate (including the extended General Mandate) and the Repurchase Mandate.

General Mandate

At the AGM, an ordinary resolution will be proposed such that the Directors be given an unconditional general mandate (i.e. the General Mandate) to allot, issue and deal with unissued Shares or underlying shares of the Company (other than by way of rights or pursuant to a share option scheme for employees or Directors of the Company and/or any of its subsidiaries or pursuant to any scrip dividend scheme or similar arrangements providing for the allotment and issue of Shares in lieu of whole or part of the dividend on Shares in accordance with the Articles) or make or grant offers, agreements, options and warrants which might require the exercise of such power, of an aggregate amount of up to 20% of the number of the issued Shares as at the date of granting of the General Mandate.

In addition, a separate ordinary resolution will further be proposed for extending the General Mandate authorising the Directors to allot, issue and deal with Shares to the extent of the Shares repurchased pursuant to the Repurchase Mandate. Details on the Repurchase Mandate are further elaborated below.

As at the Latest Practicable Date, the Company has an aggregate of 880,838,000 Shares in issue. Subject to the passing of the resolutions for the approval of the General Mandate and on the basis that no further Shares are issued or repurchased between the Latest Practicable Date and the date of the AGM, the Company would be allowed under the General Mandate to allot, issue and deal with a maximum of 176,167,600 Shares. The Directors wish to state that they have no immediate plans or intention to exercise the General Mandate or the extended General Mandate for any fund raising activities (including but not limited to consideration issue or other similar issue or transaction) and have no other fund raising activities (whether that would utilise the General Mandate/the extended General Mandate or not) as at the Latest Practicable Date.

Repurchase Mandate

At the AGM, an ordinary resolution will also be proposed such that the Directors be given an unconditional general mandate to repurchase Shares (i.e. the Repurchase Mandate) on the Stock Exchange of an aggregate amount of up to 10% of the number of the issued Shares as at the date of granting of the Repurchase Mandate.

Subject to the passing of the resolution for the approval of the Repurchase Mandate and on the basis that no further Shares are issued or repurchased between the Latest Practicable Date and the date of the AGM, the Company would be allowed under the Repurchase Mandate to repurchase a maximum of 88,083,800 Shares. As at the Latest Practicable Date, the Directors have no immediate plans to repurchase any Shares pursuant to the Repurchase Mandate.

The General Mandate and the Repurchase Mandate would expire at the earliest of: (a) the conclusion of the next annual general meeting of the Company following the AGM; or (b) the expiration of the period within which the next annual general meeting of the Company is required by the Articles or the applicable laws of the Cayman Islands to be held; or (c) revocation or variation by an ordinary resolution of the Shareholders in a general meeting prior to the next annual general meeting of the Company.

An explanatory statement in connection with the Repurchase Mandate is set out in Appendix I to this circular. The explanatory statement contains all the requisite information required under the Listing Rules to be given to the Shareholders to enable them to make an informed decision on whether to vote for or against the resolution approving the Repurchase Mandate.

RE-ELECTION OF RETIRING DIRECTORS AND APPOINTMENT OF DIRECTOR

According to Article 84, at each annual general meeting of the Company, one-third of the Directors for the time being (or, if their number is not a multiple of three (3), the number nearest to but not less than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement at an annual general meeting of the Company at least once every three years.

According to Article 83(3), any Director appointed by the Board as an additional Director shall hold office only until the next following annual general meeting of the Company and shall then be eligible for re-election.

Thus, in accordance with Articles 83(3) and 84 of the Articles, Mr. Su Hongbo, Mr. Suen Man Fung, Mr. Wong Yuk Lun, Alan and Dr. Wang Guiping will retire at the AGM and, being eligible, offer themselves for re-election.

Mr. Su Hongbo has informed the Board that he would not offer himself for re-election at the AGM due to his own decision to devote more time to his personal engagements. He has confirmed that his retirement is not due to any disagreement with the Board and there is no other matter relating to his retirement that needs to be brought to the attention of the Shareholders.

The Board would like to thank Mr. Su Hongbo for his contributions to the Company during his tenure of office.

The Board would like to propose the appointment of Ms. Qin Yuanling as an executive Director. The appointment of Ms. Qin Yuanling is subject to the approval of the Shareholders at the AGM. The term of office of Ms. Qin Yuanling will commence from the date on which approval of her appointment by the Shareholders is obtained at the AGM.

Nomination procedures for Directors and Recommendations of the Nomination Committee

The Nomination Committee shall recommend to the Board on the appointment of Directors (including independent non-executive Directors) having regard (i) the proposed candidates' qualification, background and experience; (ii) independence of candidates for independent non-executive Directors, which is assessed with reference to the factors set out in Rule 3.13 of the Listing Rules and any other factors deemed appropriate by the Nomination Committee or the Board; and (iii) the diversity of the Board in all aspects, including gender, age, cultural and educational background, professional experience, skills, knowledge and work experience.

The Nomination Committee has assessed the independence of each of the independent non-executive Directors based on the independent criteria as set out in Rule 3.13 of the Listing Rules by reviewing the written confirmation of independence for 2020 submitted to the Company by each of them, and confirmed that all of them are independent. In addition, the Nomination Committee has assessed and is satisfied with the performance of the retiring Directors for the year ended 31 December 2020.

In particular, the Nomination Committee is also of the view that each Director who is proposed to be subject to re-election and appointment at the AGM would bring to the Board his/her own perspective, skills and experience, as further described in his/her biographies in Appendix II to this circular. Therefore, in response to the recommendation of the Nomination Committee, the Board recommended the appointment of Ms. Qin Yuanling and the re-election of Mr. Suen Man Fung, Mr. Wong Yuk Lun, Alan and Dr. Wang Guiping as Directors at the AGM. As a good corporate governance practice, each of the retiring Directors who has offered himself/herself for re-election, has abstained from voting at the relevant Board meeting on the resolution to recommend his/her re-election by the Shareholders at the AGM.

Brief biographical details of the Directors who are proposed to be re-elected and appointed at the AGM are set out in Appendix II to this circular.

REFRESHMENT OF SCHEME MANDATE LIMIT

The Share Option Scheme adopted by the Company on 11 February 2014 will remain in force for a period of 10 years from 11 February 2014. Apart from the Share Option Scheme, the Company has no other share option scheme currently in force.

At the annual general meeting of the Company on 28 June 2019 (the "2019 AGM"), the then Scheme Mandate Limit was refreshed to 88,083,800 Shares, being 10% of the number of the Shares in issue as at the date of the 2019 AGM. Before the 2019 AGM, there were 73,420,000 outstanding Share Options (the "Outstanding Share Options") granted but yet to be exercised under the Share Option Scheme and any other share option scheme of the Company.

On 25 January 2021, the Directors were in a view of the fact that the recent performance of the Share price, the exercise prices of the Outstanding Share Options are much higher than the recent market prices of the Shares, the Directors considered that the Outstanding Share Options can no longer serve the purpose to motivate the grantees to continuously work to the benefit of the Group and to provide incentives or rewards to the grantees for their contribution to the Group. Therefore, the Outstanding Share Options were cancelled with effect from 25 January 2021 (the "Cancellation of Outstanding Share Options") in accordance with the terms of the Share Option Scheme. No compensation is payable to the grantees for the Cancellation of Outstanding Share Options. Prior to the Cancellation of Outstanding Share Options, the maximum number of Share Options available to be granted under the existing Scheme Mandate Limit is 88,083,800 Share Options.

On 28 July 2021, the Directors granted a total of 88,080,000 Share Options under the Share Option Scheme to subscribe for an aggregate of 88,080,000 Shares of HK\$0.01 each in the share capital of the Company (the "New Share Options"), of which 44,040,000 New Share Options were granted to the eligible employees of the Group and 44,040,000 New Share Options were granted to the eligible consultants of the Group, at an exercise price of HK\$0.083 each per Share. Save as disclosed above, there were no other Share Options were granted as at the Latest Practicable Date, and none of the New Share Options were exercised, lapsed or cancelled.

On the basis of 880,838,000 Shares in issue as at the Latest Practicable Date, and assuming there is no further issue or repurchase of Shares prior to the AGM; and the Refreshment of Scheme Mandate Limit is approved by the Shareholders at the AGM; and taking into account the New Share Options granted under the Share Option Scheme to subscribe for up to a total of 88,080,000 Shares, the Company may grant Share Options under the Share Option Scheme and any other share option scheme of the Company (if any) to eligible participants conferring the right to subscribe for not exceeding 88,083,800 Shares which, when aggregated with 88,080,000 Shares that may be issued under the New Share Options (amounting to 176,163,800 Shares which represents approximately 20% of the total number of Shares in issue as at the Latest Practicable Date), is within the said limit of 30% of the total number of Shares in issue from time to time as required under the Share Option Scheme.

As at the Latest Practicable Date, the maximum number of Share Options available to be granted under the existing Scheme Mandate Limit is 3,800 Share Options and thus the Company had almost fully utilised the existing Scheme Mandate Limit. The Directors consider that the Refreshment of Scheme Mandate Limit is in the interests of the Company and the Shareholders as a whole because it enables the Company to reward appropriately and motivate the eligible participants under the Share Option Scheme with greater flexibility.

The Refreshment of Scheme Mandate Limit is conditional upon:

- (i) the passing of an ordinary resolution to approve the Refreshment of Scheme Mandate Limit at the AGM; and
- (ii) the Listing Committee of the Stock Exchange granting the listing of, and permission to deal in, the Shares (representing a maximum of 10% of the number of issued Shares as at the date of passing the resolution of Refreshment of Scheme Mandate Limit at the AGM) which may fall to be issued upon the exercise of the Share Options to be granted under the Share Option Scheme and any other share option scheme of the Company.

Application will be made to the Stock Exchange for the listing of, and permission to deal in the Shares, representing 10% of the number of issued Shares at the AGM, which may fall to be issued upon the exercise of the Share Options that may be granted under the refreshed Scheme Mandate Limit.

AGM

A notice convening the AGM to be held at Room 2302, 23/F., China Insurance Group Building, 141 Des Voeux Road Central, Central, Hong Kong on Thursday, 30 September 2021 at 4:30 p.m. is set out on pages 21 to 26 of this circular. Ordinary resolutions will be proposed at the AGM to approve, among other things, the proposed grant of the General Mandate (including the extended General Mandate) and the Repurchase Mandate, the proposed re-election of Directors and appointment of Director, and the proposed Refreshment of Scheme Mandate Limit.

A form of proxy for use at the AGM is enclosed with this circular and such form of proxy is also published at the websites of the Stock Exchange at www.hkexnews.hk and of the Company at www.hsihl.com. Whether or not you are able to attend the AGM, you are requested to complete the accompanying form of proxy in accordance with the instructions printed thereon and deposit the same at the Company's Hong Kong branch share registrar, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong as soon as possible and in any event not less than 48 hours before (i.e. no later than 4:30 p.m. (Hong Kong Time) on Tuesday, 28 September 2021) the time appointed for the holding of the AGM or its adjournment. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish.

All the resolutions proposed to be approved at the AGM will be taken by poll and an announcement will be made by the Company after the AGM on the results of the AGM.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

RECOMMENDATION

The Directors (including all the independent non-executive Directors) consider the proposed grant of the General Mandate (including the extended General Mandate) and the Repurchase Mandate, the proposed re-election of retiring Directors and appointment of Director, and the proposed Refreshment of Scheme Mandate Limit are in the interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions to be proposed at the AGM.

GENERAL

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder is required to abstain from voting on any resolutions to be proposed at the AGM.

Yours faithfully
For and on behalf of the Board
Huisheng International Holdings Limited
Chan Chi Ching
Executive Director

This Appendix serves as an explanatory statement, as required by the Listing Rules, to provide requisite information to you for your consideration of the Repurchase Mandate.

1. REPURCHASE OF SECURITIES FROM CORE CONNECTED PARTIES

The Listing Rules prohibit the Company from knowingly purchasing its securities on the Stock Exchange from a "core connected person", that is, a director, chief executive or substantial shareholder of the Company or any of its subsidiaries or their respective close associates (as defined in the Listing Rules) and a core connected person is prohibited from knowingly selling to the Company his/her/its securities of the Company.

No core connected person of the Company has notified the Company that he/she/it has a present intention to sell any Shares to the Company nor has any such core connected person undertaken not to sell any of the Shares held by him/her/it to the Company in the event that the Repurchase Mandate is passed.

2. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 880,838,000 fully paid Shares.

Subject to the passing of the proposed resolution for the approval of the Repurchase Mandate and on the basis that no further Shares are issued or repurchased by the Company prior to the AGM, the Company will be allowed under the Repurchase Mandate to repurchase a maximum of 88,083,800 fully paid Shares, representing approximately 10% of the number of the issued Shares as at the date of passing of the resolution.

3. REASONS FOR THE REPURCHASE

The Directors believe that the Repurchase Mandate is in the best interests of the Company and the Shareholders as a whole. An exercise of the Repurchase Mandate may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net assets per Share and/or earnings per Share and will only be made when the Directors believe that a repurchase will benefit the Company and the Shareholders as a whole.

4. FUNDING OF REPURCHASES

Pursuant to the Repurchase Mandate, repurchases would be funded entirely from the Company's available cash flow or working capital facilities which will be funds legally available under the Cayman Islands law and the memorandum and articles of association of the Company for such purpose.

An exercise of the Repurchase Mandate in full may have a material adverse impact on the working capital and gearing position of the Company compared with those as at 31 December 2020, being the date of its latest published audited consolidated accounts. The Directors do not, however, intend to make any repurchase in circumstances that would have a material adverse impact on the working capital or gearing position of the Company.

5. SHARE PRICES

The highest and lowest prices at which the Shares have traded on the Stock Exchange in each of the previous twelve calendar months immediately prior to the Latest Practicable Date were as follows:

	Highest HK\$	~	Lowest
2020			
August	0.101	0.067	
September	0.093	0.087	
October	0.083	0.071	
November	0.088	0.070	
December	0.170	0.075	
2021			
January	0.142	0.096	
February	0.135	0.098	
March	0.125	0.094	
April	N/A ^(Note)	N/A ^(Note)	
May	N/A ^(Note)	N/A ^(Note)	
June	N/A ^(Note)	N/A ^(Note)	
July	0.092	0.075	
August (up to the Latest Practicable Date)	0.089	0.072	

Note: Trading in the Shares on the Stock Exchange has been suspended during 1 April 2021 to 30 June 2021.

6. DISCLOSURE OF INTERESTS AND MINIMUM PUBLIC HOLDING

None of the Directors or, to the best of their knowledge having made all reasonable enquiries, their close associates, have any present intention to sell to the Company or its subsidiaries any of the Shares in the Company if the Repurchase Mandate is approved at the AGM.

The Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the powers of the Company to make repurchases pursuant to the Repurchase Mandate in accordance with the Listing Rules and applicable laws of the Cayman Islands.

If a Shareholder's proportionate interest in the voting rights of the Company increases on the Company exercising its powers to repurchase Shares pursuant to the Repurchase Mandate, such increase will be treated as an acquisition for the purposes of Rule 32 of the Takeovers Code. As a result, a Shareholder or group of Shareholders acting in concert could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, there are no Shareholders interested in more than 10% of the Shares then in issue.

To the best of the Directors' knowledge, information and belief, on the basis of there are no Shareholders who are interested in more than 10% of Shares, an exercise of the Repurchase Mandate in full will not result in any Shareholders becoming obliged to make a mandatory offer under Rule 26 of the Takeovers Code.

The Directors have no intention to exercise the Repurchase Mandate to such an extent that will result in a requirement of the Shareholders, or any other persons to make a general offer under the Takeovers Code or the number of Shares in the hands of the public falling below the prescribed minimum percentage of 25%.

7. SHARES REPURCHASE MADE BY THE COMPANY

The Company had not purchased any of its Shares (whether on the Stock Exchange or otherwise) during the previous six months immediately prior to the Latest Practicable Date.

APPENDIX II

DETAILS OF DIRECTORS PROPOSED TO BE RE-ELECTED AND APPOINTED AT THE AGM

Details of the Directors who will retire from office and appoint at the AGM, are set out below:

(1) MS. QIN YUANLING ("MS. QIN")

Qin Yuanling was born in October 1965 and studied at Changde Fundamental University (常德基礎大學) majoring in Electrical Automation from 1984 to 1987. From July 1987 to January 2000, she worked at Changde Cable Power Plant* (常德有線電廠). From January 2000 to October 2006, she worked at Huda Yuancheng Group Company Limited* (湖大遠程集團有限公司). From October 2009 to December 2012, she worked at Changde Jinda Commodity Concrete Company Limited* (常德市金達商品砼有限責任公司). She joined Hunan Huisheng Meat Products Company Limited* (湖南惠生肉業有限公司) ("Hunan Huisheng") in February 2013 and successively worked at the general department and finance department. Since May 2019, she has been a director of Hunan Huisheng.

Ms. Qin is proposed to be appointed as an executive Director for an initial term of 3 years, and her appointment is renewable automatically for successive terms of one year after the expiry of the term of appointment, unless terminated by not less than three months' notice in writing served by either party, and is subject to retirement by rotation and re-election in accordance with the Articles. The term of office of Ms. Qin's appointment will commence from the date on which approval of her appointment by the Shareholders is obtained at the AGM, Ms. Qin will be entitled to a director's remuneration of HK\$150,000 per annum, which is determined by reference to her duties and responsibilities within the Company, the Company's remuneration policy and the market salary range for the position.

Save as disclosed above, as at the Latest Practicable Date, (i) Ms. Qin does not hold any other position in the Company or its subsidiaries; (ii) she does not hold any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) she does not, and is not deemed to have any interests or short positions in any other shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO; and (iv) she does not have any relationship with any directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, there are no other information related to Ms. Qin that are required to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there is no other matter which needs to be brought to the attention of the Shareholders.

* For identification purpose only

DETAILS OF DIRECTORS PROPOSED TO BE RE-ELECTED AND APPOINTED AT THE AGM

(2) MR. SUEN MAN FUNG ("MR. SUEN")

Mr. Suen Man Fung, aged 34, was appointed as an executive Director on 17 July 2018 and a member of the Investment and Treasury Committee since 21 May 2019. He is also a director of various subsidiaries of the Group. Mr. Suen holds a Bachelor of Science in Mathematics from The Hong Kong University of Science and Technology in 2011. Mr. Suen has board working experience in property management as well as financial investment industries. He is currently working in a managerial role in a financial institution in Hong Kong.

Mr. Suen has entered into a service contract (the "Service Contract of Mr. Suen") with the Company for an initial term of 3 years commencing from 17 July 2021 as an executive Director which is renewable automatically for successive terms of one year after the expiry of the term of appointment, unless terminated by not less than three months' notice in writing served by either party, and is subject to retirement by rotation and re-election in accordance with the Articles. Pursuant to the Service Contract of Mr. Suen, Mr. Suen is entitled to a director's remuneration of HK\$360,000 per annum, which is determined by reference to his duties and responsibilities within the Company, the Company's remuneration policy and the market salary range for the position.

Save as disclosed above, as at the Latest Practicable Date, (i) Mr. Suen does not hold any other position in the Company or its subsidiaries; (ii) he does not hold any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) he does not, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO; and (iv) he does not have any relationship with any directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, there are no other information related to Mr. Suen that are required to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there is no other matter which needs to be brought to the attention of the Shareholders.

DETAILS OF DIRECTORS PROPOSED TO BE RE-ELECTED AND APPOINTED AT THE AGM

(3) MR. WONG YUK LUN, ALAN ("MR. ALAN WONG")

Mr. Wong Yuk Lun, Alan, aged 46, was appointed as an independent non-executive Director on 6 July 2017. He is a member of the audit committee, the nomination committee and the remuneration committee. Mr. Alan Wong holds a bachelor's degree in Accounting and Finance in University of Sunderland. Mr. Wong had been working with various accounting firms and commercial companies and has over 20 years of experience in merger and acquisitions, financial management, taxation, audit and non-audit services.

Mr. Alan Wong is currently an executive director of Nova Group Holdings Limited (Stock code: 1360, a company listed on the main board of the Stock Exchange), an independent non-executive director of Smart City Development Holdings Limited (Stock code: 8268, formerly known as Deson Construction International Holdings Limited, a company listed on the GEM of the Stock Exchange) and Temir Corp. (Stock code: TMRR, a company listed on OTCQB Venture Market).

Mr. Alan Wong was an independent non-executive director of TUS International Limited (Stock code: 872) from 2 September 2014 to 17 July 2020 and Bolina Holding Co., Ltd. (Stock code: 1190) from 7 July 2016 to 27 March 2017. Both of the companies are listed on the main board of the Stock Exchange. He was also an independent non-executive director of Tech Pro Technology Development Limited (Stock code:3823) from 24 May 2019 to 2 March 2020, a company formerly listed on the main board of the Stock Exchange.

Mr. Alan Wong has entered into a letter of appointment (the "Letter of Appointment") with the Company for an initial term of 3 years commencing from 7 June 2020 as an independent non-executive Director which is renewable automatically for successive terms of one year after the expiry of the term of appointment, unless terminated by not less than three months' notice in writing served by either party, and is subject to retirement by rotation and re-election in accordance with the Articles. Pursuant to the Letter of Appointment, he is entitled to a director's remuneration of HK\$120,000 per annum, which is determined by reference to his duties and responsibilities within the Company, the Company's remuneration policy and the market salary range for the position.

Mr. Alan Wong has confirmed that he meets the independence criteria as set out in Rule 3.13 of the Listing Rules.

APPENDIX II

DETAILS OF DIRECTORS PROPOSED TO BE RE-ELECTED AND APPOINTED AT THE AGM

Save as disclosed above, as at the Latest Practicable Date, (i) Mr. Alan Wong does not hold any other position in the Company or its subsidiaries; (ii) he does not hold any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) he does not, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO; and (iv) he does not have any relationship with any directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, there are no other information related to Mr. Alan Wong that are required to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there is no other matter which needs to be brought to the attention of the Shareholders.

(4) DR. WANG GUIPING ("DR. WANG")

Dr. Wang Guiping (王貴平), aged 48, was appointed as an independent non-executive Director on 29 October 2020. He is an expert in animal microbiology and immunology. He is currently a deputy professor and tutor of master of Hunan Agricultural University* (湖南農業大學). Dr. Wang has been involved in various research projects and has published numbers of articles. Dr. Wang obtained his doctorate degree in clinical veterinary science from Hunan Agricultural University* (湖南農業大學) in 2014.

Dr. Wang has entered into a letter of appointment (the "Letter of Appointment") with the Company for an initial term of 3 years commencing from 29 October 2020 as an independent non-executive Director which is renewable automatically for successive terms of one year after the expiry of the term of appointment, unless terminated by not less than three months' notice in writing served by either party, and is subject to retirement by rotation and re-election in accordance with the Articles. Pursuant to the Letter of Appointment, he is entitled to a director's remuneration of RMB50,000 per annum, which is determined by reference to his duties and responsibilities within the Company, the Company's remuneration policy and the market salary range for the position.

Dr. Wang has confirmed that he meets the independence criteria as set out in Rule 3.13 of the Listing Rules.

APPENDIX II

DETAILS OF DIRECTORS PROPOSED TO BE RE-ELECTED AND APPOINTED AT THE AGM

Save as disclosed above, as at the Latest Practicable Date, (i) Dr. Wang does not hold any other position in the Company or its subsidiaries; (ii) he does not hold any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) he does not, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO; and (iv) he does not have any relationship with any directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, there are no other information related to Dr. Wang that are required to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there is no other matter which needs to be brought to the attention of the Shareholders.



HUISHENG INTERNATIONAL HOLDINGS LIMITED 惠生國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1340)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that an annual general meeting of Huisheng International Holdings Limited (the "**Company**") will be held at held at Room 2302, 23/F., China Insurance Group Building, 141 Des Voeux Road Central, Central, Hong Kong on Thursday, 30 September 2021 at 4:30 p.m. for the following purposes:

- to receive and consider the audited consolidated financial statements and the reports
 of the directors (the "Directors") and auditors of the Company for the year ended 31
 December 2020;
- 2. (a) to appoint Ms. Qin Yuanling as an executive Director;
 - (b) to re-elect Mr. Suen Man Fung as an executive Director;
 - (c) to re-elect Mr. Wong Yuk Lun, Alan as an independent non-executive Director; and
 - (d) to re-elect Dr. Wang Guiping as an independent non-executive Director.
- 3. to re-appoint HLB Hodgson Impey Cheng Limited as the auditors of the Company and to authorise the board of Directors to fix their remuneration;

and, as special business, consider and, if thought fit, pass the following resolutions as ordinary resolutions:

4. "THAT:

- (a) subject to paragraph (c) below, pursuant to the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), the exercise by the Directors during the Relevant Period (as defined below) of all the powers of the Company to allot, issue and deal with unissued shares of the Company (the "Shares") and to make or grant offers, agreements and options, including warrants to subscribe for Shares, which might require the exercise of such powers be and the same is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) above shall authorise the Directors during the Relevant Period to make or grant offers, agreements and options which might require the exercise of such powers after the end of the Relevant Period;
- the aggregate nominal amount of share capital allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to options or otherwise) by the Directors pursuant to the approval in paragraph (a) above, otherwise than pursuant to (i) a Rights Issue (as defined below); or (ii) the exercise of any options granted under the existing share option scheme of the Company; or (iii) any scrip dividend or similar arrangements providing for the allotment and issue of Shares in lieu of the whole or part of a dividend on Shares in accordance with the articles of association of the Company in force from time to time; or (iv) any issue of Shares upon the exercise of rights of subscription or conversion under the terms of any warrants of the Company or any securities which are convertible into Shares, shall not exceed the aggregate of:
 - (aa) 20 per cent. of the number of issued Shares on the date of the passing of this resolution; and
 - (bb) (if the Directors are so authorised by a separate ordinary resolution of the shareholders of the Company) the nominal amount of any share capital of the Company repurchased by the Company subsequent to the passing of this resolution (up to a maximum equivalent to 10 per cent. of the number of issued Shares on the date of the passing of resolution no. 6),

and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly; and

(d) for the purposes of this resolution:

"Relevant Period" means the period from the date of the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; or
- (iii) the revocation or variation of the authority given under this resolution by an ordinary resolution of the shareholders in general meeting.

"Rights Issue" means an offer of Shares, or offer or issue of warrants, options or other securities giving rights to subscribe for Shares open for a period fixed by the Directors to holders of Shares on the register on a fixed record date in proportion to their then holdings of Shares (subject to such exclusion or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements, or having regard to any restrictions or obligations under the laws of, or the requirements of, or the expense or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction outside Hong Kong or any recognised regulatory body or any stock exchange outside Hong Kong)."

5. "THAT:

(a) subject to paragraph (b) of this Resolution, the exercise by the Directors during the Relevant Period as defined in Resolution 4(d) of all powers of the Company to repurchase issued shares in the capital of the Company on the Stock Exchange or any other stock exchange on which the shares of the Company may be listed and recognised by the Securities and Futures Commission of Hong Kong (the "Securities and Futures Commission") and the Stock Exchange for such purpose, and otherwise in accordance with the rules and regulations of the Securities and Futures Commission, the Stock Exchange or of any other stock exchange as amended from time to time and all applicable laws in this regard, be and the same is hereby generally and unconditionally approved;

- (b) the aggregate number of shares of the Company in issue which may be repurchased by the Company pursuant to the approval in paragraph (a) of this Resolution during the Relevant Period shall not exceed 10 per cent. of the aggregate number of the shares of the Company in issue as at the date of passing of this Resolution and the said approval shall be limited accordingly; and
- (c) for the purpose of this Resolution, "Relevant Period" shall have the same meaning as in Resolution 4(d)."
- 6. "THAT the Directors be and they are hereby authorised to exercise the authority referred to in paragraph (a) of resolution no. 4 above in respect of the share capital of the Company referred to in sub-paragraph (bb) of paragraph (c) of such resolution."
- 7. "THAT subject to the Stock Exchange granting the listing of, and permission to deal in, the Shares to be issued pursuant to the exercise of options which may be granted under the Scheme Mandate Limit (as defined below) and pursuant to the share option scheme of the Company adopted on 11 February 2014 (the "Share Option Scheme"), approval be and is hereby generally and unconditionally granted for refreshing and renewing the Scheme Mandate Limit (as defined below) under the Share Option Scheme provided that (i) the total number of Shares which may be allotted and issued upon the exercise of the options to be granted under the Share Option Scheme and other share option schemes of the Company shall not exceed 10 per cent. of the number of issued Shares as at the date of the passing of this resolution (the "Scheme Mandate Limit"); and (ii) the overall limit on the number of Shares which may be issued upon the exercise of all options to be granted and yet to be exercised under the Share Option Scheme and other share option schemes of the Company must not exceed 30 per cent. of the number of issued Shares from time to time and that the Directors be and are hereby authorised, at their absolute discretion, to grant options under the Share Option Scheme up to the Scheme Mandate Limit and to exercise all the powers of the Company to allot, issue and deal with the Shares pursuant to the exercise of such options."

By order of the Board **Huisheng International Holdings Limited Chan Chi Ching**Executive Director

Hong Kong, 31 August 2021

Registered office: Head office in the PRC:

Cricket Square Unit 4

Hutchins Drive Hejiaping Housing Committee
P.O. Box 2681 Deshan Town

Grand Cayman KY1-1111 Economic and Technological Development Zone

Changde City, Hunan Province

PRC

Principal place of business in Hong Kong:

Room 1604, 16/F, Tower 1, Silvercord 30 Canton Road Tsim Sha Tsui

Kowloon, Hong Kong

Notes:

Cayman Islands

- A member entitled to attend and vote at the meeting convened by the above notice is entitled to appoint one or more
 proxy to attend and, subject to the provisions of the articles of association of the Company, vote in his stead. A
 proxy need not be a member of the Company.
- 2. The register of members will be closed from Monday, 27 September 2021 to Thursday, 30 September 2021 both days inclusive, during which no transfer of shares will be registered. In order to be entitled to attend and vote at the annual general meeting of the Company to be held on Thursday, 30 September 2021, all properly completed transfer forms accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong no later than 4:30 p.m. (Hong Kong Time) on Friday, 24 September 2021.
- 3. In order to be valid, the form of proxy, together with a power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority must be deposited at the Company's Hong Kong branch share registrar, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong as soon as possible and in any event not less than 48 hours before (i.e. no later than 4:30 p.m. (Hong Kong Time) on Tuesday, 28 September 2021) the time appointed for the holding of the annual general meeting or any adjournment thereof. Completion and return of a form of proxy will not preclude a shareholder of the Company from attending in person and voting at the annual general meeting or any adjournment thereof, should he/she/it so wish.
- 4. In the case of joint holders of shares, any one of such holders may vote at the annual general meeting, either personally or by proxy, in respect of such share as if he was solely entitled thereto, but if more than one of such joint holders are present at the annual general meeting personally or by proxy, that one of the said persons so present whose name stands first on the register of members of the Company in respect of such shares shall alone be entitled to vote in respect thereof.

- 5. In relation to proposed resolutions nos. 4 and 6 above, approval is being sought from the shareholders for the grant to the Directors of a general mandate to authorise the allotment and issue of shares of the Company under the Listing Rules. The Directors wish to state that they have no immediate plans to buy back any existing shares or to issue any new shares (other than pursuant to the exercise of share options granted or to be granted by the Company, if any) pursuant to the relevant mandates.
- 6. In relation to proposed resolution no. 5 above, the Directors wish to state that they will exercise the powers conferred thereby to repurchase Shares in circumstances which they deem appropriate for the benefit of the shareholders of the Company. An explanatory statement containing the information necessary to enable the shareholders to make an informed decision to vote on the proposed resolution as required by the Listing Rules is set out in Appendix Ito this circular.
- 7. All resolutions will be conducted by way of a poll.
- 8. If tropical cyclone warning signal no. 8 or above or "extreme conditions" caused by super typhoons or a "black" rainstorm warning signal is in force at 12:00 noon on 30 September 2021, the meeting will be postponed and further announcement for details of alternative meeting arrangements will be made. The meeting will be held as scheduled even when tropical cyclone warning signal no. 3 or below is hoisted, or an amber or red rainstorm warning signal is in force. You should make your own decision as to whether you would attend the meeting under bad weather conditions and if you should choose to do so, you are advised to exercise care and caution.